GenSight Biologics (SIGHT) Q1 2025 TU earnings summary

Executive summary

• Cash and cash equivalents totaled €0.9 million as of March 31, 2025, with operations funded until early June 2025 due to disciplined spending controls.

• Fundraising activities are underway to extend the cash runway and support the RECOVER Phase III trial and MHRA marketing application for LUMEVOQⓇ.

• Discussions with the French agency ANSM on the early access program (AAC) for LUMEVOQⓇ are progressing, with a decision expected soon.

Financial highlights

• Cash position declined from €2.5 million on December 31, 2024, to €0.9 million on March 31, 2025.

• Additional €0.9 million raised via equity-with-warrants financing in March 2025; €1.1 million in Research Tax Credit expected in April.

• Current funds projected to last until early June 2025, necessitating further fundraising.

Outlook and guidance

• RECOVER Phase III trial targeted to begin in H1 2026, with study design being refined per FDA and EMA feedback.

• UK MHRA marketing application for LUMEVOQⓇ planned, with regulatory interactions set for H2 2025.

• Company proactively planning for November 2026 rebate obligations related to the AAC program.